HCW Biologics Inc
HCWB9.150USD
-0.900-8.96%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
407.55MCap. mercado
PérdidaP/E TTM
Más Datos de HCW Biologics Inc Compañía
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Información de la empresa
Código de la empresaHCWB
Nombre de la empresaHCW Biologics Inc
Fecha de salida a bolsaJul 20, 2021
Fundada en2018
Director ejecutivoDr. Hing C. Wong, Ph.D.
Número de empleados36
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 20
Dirección2929 N Commerce Pkwy
CiudadMIRAMAR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33025
Teléfono19548422024
Sitio Webhttps://hcwbiologics.com/
Código de la empresaHCWB
Fecha de salida a bolsaJul 20, 2021
Fundada en2018
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
+0.11%
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
493.86K
+23.05%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
12.08K
+80.41%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President of Business Development
Senior Vice President of Business Development
5.72K
+20.23%
Mr. Gary M. Winer
Mr. Gary M. Winer
Independent Director
Independent Director
2.73K
+543.06%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President of Clinical Operations
Chief Scientific Officer, Vice President of Clinical Operations
1.94K
+0.05%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: hace 19 horas
Hora de actualización: hace 19 horas
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Estadísticas de accionistas
Accionista
Proporción
Wong (Hing C)
43.96%
Armistice Capital LLC
4.50%
Byam (Rebecca)
3.83%
Garrett (Scott T)
1.08%
Avantax Planning Partners, Inc
0.62%
Other
46.01%
Tipo
Accionista
Proporción
Individual Investor
50.05%
Hedge Fund
4.57%
Investment Advisor
1.54%
Investment Advisor/Hedge Fund
1.32%
Research Firm
0.03%
Other
42.48%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
37
530.40K
48.29%
+53.17K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
2022Q4
32
22.28M
62.20%
-3.33M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Wong (Hing C)
16.05M
35.73%
--
--
Nov 22, 2024
Armistice Capital LLC
2.02M
4.5%
+2.02M
--
Dec 31, 2024
Byam (Rebecca)
1.38M
3.08%
--
--
Apr 15, 2024
Garrett (Scott T)
267.86K
0.6%
+142.86K
+114.29%
Apr 15, 2024
Avantax Planning Partners, Inc
279.54K
0.62%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
37.68K
0.08%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
181.96K
0.4%
-1.30K
-0.71%
Dec 31, 2024
Flowers (Lee)
190.24K
0.42%
+71.43K
+60.12%
Feb 20, 2024
Cresset Asset Management, LLC
131.99K
0.29%
--
--
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos